Fetal Haemoglobin and Cerebral and Peripheral Oxygenation.
Launched by MEDICAL UNIVERSITY OF GRAZ · Mar 15, 2021
Trial Information
Current as of June 06, 2025
Completed
Keywords
ClinConnect Summary
During gestation the main fetal oxygen carrier is fetal hemoglobin (HbF). HbF exhibits a significantly higher affinity for oxygen when compared to adult hemoglobin (HbA), which makes it more suitable for oxygen extraction at the lower partial oxygen pressures in utero. Although the regulation of HbF expression is determined developmentally, recent studies report a respectable variation in the fraction of HbF in neonates.
Such data suggest that the differences in HbF expression could affect end-tissue oxygenation in neonates.
The methodology for measuring oxygen saturation and extraction i...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Term and preterm neonates admitted to the neonatal intensive care unit (NICU)
- • Decision to conduct full life support
- • Written informed consent
- Exclusion Criteria:
- • No decision to conduct full life support
- • No written informed consent
- • Congenital malformations
- • Family history of haemoglobinopathies (e.g. sickle cell anaemia, thalassaemia)
About Medical University Of Graz
The Medical University of Graz, a leading institution in Austria, is dedicated to advancing medical knowledge and improving patient care through innovative research and clinical trials. Renowned for its interdisciplinary approach, the university collaborates with various healthcare professionals and researchers to explore cutting-edge therapies and treatments. With a commitment to ethical standards and patient safety, the Medical University of Graz actively contributes to the global medical community by facilitating rigorous clinical trials that aim to translate scientific discoveries into practical applications for improved health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Graz, Styria, Austria
Patients applied
Trial Officials
Gerhard Pichler, Prof
Principal Investigator
Medical University of Graz
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials